Neurocrine Biosciences Exercises its Option with Idorsia for ACT-709478

Share this

Neurocrine Biosciences Exercises its Option with Idorsia for ACT-709478


  • Idorsia to receive $45M upfront in cash- $365M for development & regulatory milestone- one-time sales threshold and royalties on sales. Additionally- will receive $7M in funding to discover- identify and develop additional novel T-type calcium channel blockers
  • Neurocrine exercises its option to license rights for ACT-709478 (post IND acceptance from the US FDA on Apr 30- 2020) for rare pediatric epilepsy. In 2019- Neurocrine and Idorsia signed a preclinical research collaboraion for ACT-709478 to treat rare pediatric epilepsy
  • ACT-709478 is an selective- orally-active and brain penetrating T-type calcium channel blocker also received the US FDA's Rare Pediatric Disease designation for rare pediatric epilepsy with completion of P-I in 2019 and expected P-II initiation in in H2'20

Click here to read full press release/ article | Ref: GlobeNewswire | Image:Twitter


Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected].

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions